The Russian FSHD registry: a first look at the cohort

The Russian FSHD registry characterizes a large national cohort of 470 patients, revealing a younger demographic profile, a predominance of 3 D4Z4 repeats, and three distinct disease trajectories that offer a framework for improved patient stratification.

The Gist

Imagine a massive, high-tech library dedicated to a specific type of book: the story of Facioscapulohumeral Muscular Dystrophy (FSHD). For a long time, Russia didn't have its own branch of this library because they lacked the "decoder ring" (a specific genetic test) to read the books properly. Without that ring, doctors could only guess the story based on how the characters looked, not what was written in their DNA.

In 2019, Russian scientists finally built their decoder ring. They used it to open a new branch of the library called the Russian FSHD Patient Registry. This paper is their "first look" at the collection they've gathered by January 2026.

Here is the story of what they found, told in simple terms:

1. The Collection Size and Who's in It

The library now holds 470 stories (patients).

• The Mix: It's almost an even split between men and women.
• The Age: The average age is about 38. This is younger than similar libraries in Europe or the US. Think of it as a library that has a lot of young adults and fewer elderly patrons.
• The Verification: About 76% of these stories were verified with the new genetic decoder ring. The rest were included because their symptoms were so classic that the ring wasn't strictly necessary to know they belonged in the FSHD section.

2. The "Glitch" in the Code (Genetics)

FSHD is caused by a glitch in a specific part of our DNA called the D4Z4 repeat. Imagine this as a string of beads on a necklace. In healthy people, the string is long. In FSHD patients, the string is too short.

• The Russian Pattern: Most Russian patients had a string with 3 beads (a very short string). This is slightly different from European patterns, where strings with 4 to 6 beads are more common. It actually looks a bit more like patterns seen in Asian populations.
• The Rule of Thumb: The shorter the string (fewer beads), the more severe the disease tends to be. The researchers found a clear link: fewer beads = harder time moving.

3. How the Story Starts (Symptoms)

When people first noticed something was wrong, what did they feel?

• The "Shoulder" Start: The most common first sign was weakness in the muscles around the shoulder blades (periscapular). Imagine trying to lift your arms and your shoulder blades feel like they are floating away from your back. This happened in nearly half the patients.
• The "Face" Surprise: The second most common sign was facial weakness (drooping smile, trouble whistling). However, many patients didn't notice this at first! They thought they just had a funny face or were tired. It was only when doctors asked detailed questions that they realized, "Oh, that's been happening for years."
• The "Leg" Start: In older patients (over 40), the trouble often started in the feet or lower legs, making it hard to walk on flat ground.

4. Three Different "Story Arcs" (Clusters)

The researchers used a computer to sort these 470 stories into three distinct "genres" or trajectories based on how the disease progressed:

1. The "Classic" Plot (The Majority): This group started young (before age 14). The story moved fast. Weakness spread quickly from the shoulders to the face and legs. By age 30, most of these patients had weakness in all major muscle groups.
2. The "Face-First" Slow Burn: A small group started with facial weakness but progressed very slowly. They kept their leg strength for a long time.
3. The "Shoulder-First" Slow Burn: Another small group started with shoulder weakness but, like the face-first group, moved very slowly. Their faces stayed strong for decades.

5. The "Real World" Impact

The researchers also asked patients about their daily lives, like a survey.

• Mobility: Surprisingly, fewer Russian patients are in wheelchairs compared to other countries. Why? Because the Russian group is younger on average. It takes time for the "story" to reach the point where walking becomes impossible.
• The "Hidden" Triggers: Some patients felt their disease got worse after big life events like pregnancy, surgery, or intense stress. It's like a car engine that runs fine until you hit a steep hill or a pothole.
• Other Health Issues: About 35% of patients had other health problems (like thyroid issues or stomach trouble), which is higher than in some other studies.

6. Why This Matters

This paper is like a map for the future.

• For Doctors: It helps them understand that FSHD isn't just one thing. It has different "speeds" and starting points. Knowing which "genre" a patient belongs to helps predict their future.
• For Researchers: Because they have a verified list of 470 people, they can now test new drugs more easily. Instead of hunting for patients, they have a ready-made team.
• For Patients: It validates their experience. It shows that even if they feel "different" from the textbook definition, they are part of a larger, understood community.

In a nutshell: Russia has built a powerful new tool to track FSHD. They found that while the disease follows some universal rules (shorter DNA strings = worse symptoms), the Russian patients are a bit younger and have a unique genetic mix. Most importantly, they discovered that the disease moves at different speeds for different people, and recognizing these patterns is the key to better care.

Technical Summary

1. Problem Statement

Facioscapulohumeral muscular dystrophy (FSHD) is a prevalent hereditary neuromuscular disorder characterized by variable expressivity and age of onset. While over 20 global patient registries exist to support natural history studies and clinical trials, Russia lacked a national registry for an extended period. This gap was primarily due to the unavailability of accessible molecular diagnostics; the standard Southern blotting method (requiring radioactive isotopes) is not used in routine Russian practice. Consequently, diagnoses were historically based solely on clinical presentation and family history, leading to incomplete data and a lack of standardized genetic confirmation. The establishment of a PCR-based diagnostic method in 2019 created the opportunity to fill this gap, necessitating a comprehensive registry to characterize the Russian FSHD population.

2. Methodology

The study describes the establishment and initial analysis of the Russian FSHD Patient Registry at the Research Centre for Medical Genetics (RCMG) in Moscow, with data collected as of January 2026.

• Cohort Recruitment: Patients were enrolled via three pathways: referral from regional genetic centers, self-application via the registry website (screening for clinical signs), and identification during genetic consultations at RCMG for unspecified myopathies.
• Data Collection:
  • Clinical Assessment: A specialized 196-item form was used, covering demographics, genetics, anamnesis, neurological exams, and specialized scales (FSHD-CS, CSS, age-corrected variants).
  • Patient-Reported Outcomes: A 62-item questionnaire assessed symptoms, triggers, and quality of life using the Facial Disability Index (FDI) and the GNE-myopathy functional activity scale (GNEM-FAS).
• Genetic Diagnostics:
  • Methodology: A validated PCR-based method was employed, involving high-molecular-weight DNA isolation from blood or fibroblasts, EcoRI restriction digestion, Pulse-Field Gel Electrophoresis (PFGE), and multiplex quantitative PCR (qPCR) with TaqMan probes.
  • Targets: The assay quantified D4Z4 repeat units (RUs) on chromosome 4 and identified the permissive 4qA haplotype.
• Statistical Analysis:
  • Descriptive statistics, Spearman's rank correlation (for RU vs. severity), and Chi-square/Fisher's exact tests were used.
  • Clustering: Hierarchical clustering (Ward's method) was applied to 215 patients with known symptom onset ages. A "delta score" (time difference between specific symptom onset and the earliest symptom) was calculated for five anatomical groups to adjust for individual timing variations.

3. Key Contributions

• First National Registry: This paper presents the first comprehensive characterization of the Russian FSHD cohort (470 participants), establishing a critical infrastructure for future clinical trials and natural history studies in Russia.
• Diagnostic Validation: It demonstrates the successful implementation of a non-radioactive, PCR-based genetic confirmation method, overcoming previous diagnostic barriers in the region.
• Phenotypic Stratification: The study introduces a novel clustering approach using delta-adjusted symptom progression, identifying three distinct disease trajectories rather than a single linear progression.
• Demographic Insights: It provides the first large-scale data on the genetic and clinical landscape of FSHD in Russia, revealing unique demographic and genetic distribution patterns compared to international cohorts.

4. Key Results

• Cohort Demographics: The registry includes 470 individuals (51% male) with a median age of 38 years (range 0–97). The cohort is notably younger than international registries (e.g., UK: ~48 years; Dutch: ~51 years).
• Genetic Confirmation: 76% (n=356) of participants had genetic confirmation.
  • FSHD1: 346 patients (276 families).
  • FSHD2: 10 patients (8 families, ~2.8% of cohort).
  • RU Distribution: The distribution of D4Z4 repeats differed from European cohorts. While 4–6 RUs were common, patients with 3 RUs formed the largest group, a pattern more similar to East Asian cohorts. Sporadic cases were significantly more prevalent in the 1–3 RU group.
• Clinical Onset and Progression:
  • Initial Symptoms: Periscapular weakness was the most common initial manifestation (46.8% after detailed history), followed by facial weakness (31.6%). Notably, facial weakness was often unnoticed by patients initially, suggesting it is frequently underreported as a primary symptom.
  • Severity: A moderate inverse correlation was found between the number of D4Z4 repeats and clinical severity (lower RU count = higher severity).
  • Probands vs. Relatives: Probands consistently presented with more severe phenotypes than their affected relatives, likely due to selective referral bias.
• Clustering Analysis: Three distinct trajectories were identified:
  1. Classic Phenotype (n=177): Onset <14 years, rapid progression, early involvement of all muscle groups.
  2. Facial-Onset Slow Progression (n=16): Early facial weakness followed by slow progression to other groups.
  3. Periscapular-Onset Slow Progression (n=22): Early shoulder/periscapular weakness with delayed facial involvement.
• Extramuscular Findings: Hearing loss, retinal angiopathy, and cardiac conduction abnormalities were observed but at lower frequencies than in older international cohorts, likely due to the younger age of the Russian cohort. Camptocormia was rare (n=5) and appeared in older patients with specific genetic profiles.
• Disability: The proportion of patients with limited mobility (6.2% using aids, 6.3% wheelchair-dependent) was significantly lower than in Dutch and UK registries, correlating with the younger median age.

5. Significance

This study establishes a robust foundation for FSHD research in Russia. The identification of a younger cohort with a predominance of 3-repeat alleles suggests that the Russian population may have a distinct genetic and clinical profile compared to Western European populations. The discovery of three heterogeneous disease trajectories via delta-adjusted clustering offers a refined framework for patient stratification, which is crucial for designing targeted clinical trials and predicting disease course. Furthermore, the registry's success in integrating genetic confirmation with detailed phenotypic data validates the utility of the PCR-based diagnostic method, ensuring that future Russian FSHD patients can be accurately diagnosed and enrolled in global therapeutic studies. The data highlights the importance of thorough anamnesis to uncover "silent" symptoms like facial weakness, which are critical for early diagnosis.